Vedolizumab in Patients With UC

Vedolizumab demonstrated significantly greater efficacy as induction and maintenance therapy for UC than placebo in patients naive to TNF antagonists and patients with TNF antagonist failure. There were numerically greater treatment differences at Week 6 among patients receiving vedolizumab who were naive to TNF antagonists than patients with TNF antagonist failure. An AGA Reading Room

Approaches to Treating Malnutrition in IBD

New study will compare the Mediterranean and specific carbohydrate diets The Crohn’s & Colitis Foundation of America (CCFA) is sponsoring what it is calling the first-ever national study of the effect of dietary interventions to treat Crohn’s disease. The study will compare the Mediterranean-style diet with the specific carbohydrate diet (SCD) in order to evaluate